6 days Ago By ABMN Staff
Alliancebernstein L.P. lessened its stake in Guardant Health, Inc.
( NASDAQ:GH – Free Report ) by 12.5% in the 4th quarter, Holdings Channel.com reports.
The firm owned 125,720 shares of the company’s stock after selling 18,000 shares during the period. Alliancebernstein L.P.
’s holdings in Guardant Health were worth $3,841,000 at the end of the most recent reporting period. Other institutional investors have also recently added to or reduced their stakes in the company. California Public Employees Retirement System increased its stake in shares of Guardant Health by 13.
8% in the 4th quarter. California Public Employees Retirement System now owns 178,470 shares of the company’s stock worth $5,452,000 after acquiring an additional 21,674 shares during the last quarter. Norges Bank acquired a new stake in Guardant Health during the fourth quarter worth about $36,438,000.
NEOS Investment Management LLC increased its position in Guardant Health by 10.9% during the fourth quarter. NEOS Investment Management LLC now owns 36,120 shares of the company’s stock worth $1,103,000 after purchasing an additional 3,553 shares during the last quarter.
Artisan Partners Limited Partnership purchased a new position in Guardant Health during the fourth quarter worth about $1,499,000. Finally, Ausdal Financial Partners Inc. acquired a new position in Guardant Health in the 4th quarter valued at about $214,000.
Hedge funds and other institutional investors own 92.60% of the company’s stock. Wall Street Analysts Forecast Growth GH has been the subject of a number of recent analyst reports.
Barclays cut their price target on shares of Guardant Health from $60.00 to $55.00 and set an “overweight” rating for the company in a report on Thursday, April 10th.
Guggenheim reissued a “buy” rating and set a $56.00 target price on shares of Guardant Health in a research note on Monday, February 24th. Mizuho initiated coverage on Guardant Health in a research note on Thursday, April 10th.
They issued an “outperform” rating and a $55.00 price target on the stock. Piper Sandler raised their price objective on Guardant Health from $34.
00 to $50.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Finally, Scotiabank boosted their price objective on shares of Guardant Health from $47.
00 to $52.00 and gave the company a “sector outperform” rating in a report on Monday, February 24th. Twenty investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock.
According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $49.00. Guardant Health Trading Up 3.
3 % Shares of NASDAQ GH opened at $45.16 on Tuesday. The stock has a market cap of $5.
57 billion, a P/E ratio of -12.69 and a beta of 1.45.
The business’s fifty day simple moving average is $43.53 and its 200-day simple moving average is $35.93.
Guardant Health, Inc. has a 12-month low of $15.81 and a 12-month high of $50.
89. Guardant Health ( NASDAQ:GH – Get Free Report ) last posted its quarterly earnings results on Thursday, February 20th. The company reported ($0.
90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15).
The company had revenue of $201.81 million during the quarter, compared to analyst estimates of $192.50 million.
Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%.
On average, equities analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.
Guardant Health Profile ( Free Report ) Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. Read More Want to see what other hedge funds are holding GH? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Guardant Health, Inc. ( NASDAQ:GH – Free Report ). Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.
com's FREE daily email newsletter ..
